Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
437
NCT04679129
Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2020
Completion: Jun 3, 2021
NCT04686994
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
Start: Dec 22, 2020
Completion: Feb 7, 2021
NCT04692025
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
Start: Dec 27, 2020
Completion: Jan 21, 2021
NCT04845646
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
Start: Mar 16, 2021
Completion: Jun 10, 2021
NCT05118516
Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects
Start: Nov 1, 2021
Completion: Dec 7, 2021
NCT05190523
Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
Phase: Phase 2
Start: Apr 6, 2022
Completion: Mar 13, 2024
NCT05287399
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Start: Aug 2, 2022
Completion: Dec 20, 2024
NCT05464628
Drug Interaction Study of ASC42 With Atorvastatin
Start: Aug 8, 2022
Completion: Aug 30, 2022
NCT05462353
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
Start: Sep 30, 2022
Completion: Jun 10, 2025
NCT05118360
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
Start: Dec 1, 2023
Completion: Jan 9, 2025